JPS6129927B2 - - Google Patents
Info
- Publication number
- JPS6129927B2 JPS6129927B2 JP57161129A JP16112982A JPS6129927B2 JP S6129927 B2 JPS6129927 B2 JP S6129927B2 JP 57161129 A JP57161129 A JP 57161129A JP 16112982 A JP16112982 A JP 16112982A JP S6129927 B2 JPS6129927 B2 JP S6129927B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- administered
- pharmaceutical composition
- arrhythmia
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 67
- 229940079593 drug Drugs 0.000 claims description 65
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 15
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 13
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 11
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000000644 isotonic solution Substances 0.000 claims description 2
- 230000003257 anti-anginal effect Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 description 20
- 230000006793 arrhythmia Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 230000000747 cardiac effect Effects 0.000 description 12
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 12
- 230000004872 arterial blood pressure Effects 0.000 description 10
- 210000004165 myocardium Anatomy 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000008602 contraction Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 230000003126 arrythmogenic effect Effects 0.000 description 7
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 7
- 229960000244 procainamide Drugs 0.000 description 7
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 6
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 6
- 229940039750 aconitine Drugs 0.000 description 6
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 6
- 229960005003 carbocromen Drugs 0.000 description 6
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 6
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229960001404 quinidine Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 5
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 206010061592 cardiac fibrillation Diseases 0.000 description 5
- 230000002600 fibrillogenic effect Effects 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000000006 Nitroglycerin Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 231100000636 lethal dose Toxicity 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- JFWLFLLRLZSBRA-UHFFFAOYSA-N 3-[(trimethylazaniumyl)amino]propanoate;dihydrate Chemical compound O.O.C[N+](C)(C)NCCC([O-])=O JFWLFLLRLZSBRA-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 239000002368 cardiac glycoside Substances 0.000 description 3
- 229940097217 cardiac glycoside Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 229930002534 steroid glycoside Natural products 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- JHPNVNIEXXLNTR-UHFFFAOYSA-O 4-(trimethylammonio)butanoic acid Chemical compound C[N+](C)(C)CCCC(O)=O JHPNVNIEXXLNTR-UHFFFAOYSA-O 0.000 description 2
- -1 Benzodixin Chemical compound 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940095990 inderal Drugs 0.000 description 2
- 230000000053 inderal effect Effects 0.000 description 2
- 230000000297 inotrophic effect Effects 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 150000008143 steroidal glycosides Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- YSCJAYPKBYRXEZ-HZPINHDXSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YSCJAYPKBYRXEZ-HZPINHDXSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000008131 Ventricular Flutter Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000005794 circulatory dysfunction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000000408 embryogenic effect Effects 0.000 description 1
- 231100000351 embryotoxic Toxicity 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=NâOâ); Hydrazines (>NâN<); Hydrazones (>NâN=) ; Imines (CâN=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
ãã®çºæã¯å»è¬ã«é¢ããããã«è©³ããã¯ãåŒæ¬
æã«ãããå¿èæ©èœäžå šãåçš®ã®åå ããçãã
äžæŽèã®ããšãå¿èâè¡ç®¡ç³»çŸæ£ã®æ²»ççšå»è¬çµ
æç©ã«é¢ããã çŸåšãäž»èŠãªéžæç匷å¿è¬è£œå€ã¯åŒ·å¿é ç³äœã§
ããããã®åŒ·å¿é ç³äœè£œå€ã«ã¯ããªãã³è£œå€ãã¹
ãããã¢ã³ãã¹è£œå€ãããçš®ã®çŸåããåŸããã
補å€ãšå ±ã«ãžãã¿ãªã¹è£œå€ãå«ãŸããïŒïŒã»
Yuã»MashkovskyïŒPharmaceutical
PreparationïŒM.ïŒMeditsina Publishing
HouseïŒ1977幎ãåç §ïŒã é ç³äœã®åºæ¬çãªæ¬ ç¹ã¯æ²»çææ°ãäœãç¹ã§ã
ããåããã®è£œå€ã®éå°æäžã«ããé倧ãªå䜵
çãããªãã¡ãæ¥æ§åŸèãé »çºæå€åçž®ãäºæ®µ
èãäžæ®µèãæ¿å®€ç³»äŒå°ã®æžéãå¿å®€æ§ç²ååã³
æ¡åŒµæå¿æ¶ååæ¢ãæ¹èµ·ãããã å¿ ç¶çãªæ¬ ç¹ã¯ãããã«ãè¬å€ã®è¡äžæ¿åºŠãšæ²»
çå¹æãšã®éã«çŽæ¥é¢ä¿ããªãããšã§ããããã®
ãããé ç³äœã¯ãã°ãã°ãèç²èãåºæ¿ããåå
äžæ¢ã«äœçšããŠæ¶ç«äžè¯ãæ¹èµ·ããã å¿èçŸæ£æ²»ççšè£œå€ã®å€ãã¯æäžè補å€ã§ã
ãããããã®å æãåºã䜿çšãããŠãããã®ã®ïŒ
ã€ã«ããã«ã€ã³ã¢ãããããããã®è¬åã¯æå€å
çž®ãå«ãçš®ã ã®äžæŽèã«å¯ŸããŠæå¹ã«é©çšãããŠ
ãããããããªãããã®è¬å€ãå¯äœçšãããªã
ã¡ãå šèº«è¡°åŒ±ãé çãåæ°ãååãäžç çãæ¶ç«
äžè¯çç¶ãæ¹èšãããããŠéèæäžããå Žåã«ã¯
å¿èã·ãšãã¯ãèµ·ããå¯èœæ§ãããããã®äžãå¿
çæ¢å¡ã®çäŸã«ãããŠã¯ãå¿çåçž®é»å®³åã³åè
è¡å§ã®äœäžãèµ·ããå¯èœæ§ããããããéåžžã«æ
éã«æäžããªããã°ãªããªãã å¹æã®é«ãè¬å€ã§ããã¢ã€ããªã³ïŒAimalinïŒ
åã³ãšãœã¢ãã³ãïŒâã«ã«ããã³é ž10âïŒïŒâã¢
ãŒããªã«ããããªãã«ïŒããšããã¢ãžããããã¯
ããªãã®ãšãã«ãšã¹ãã«ãããæ¬è³ªçã«åæ§ã®æ¬
ç¹ãæããŠããããããã®è¬å€ã¯ããã«å¿çã®å
çž®æ§ãäœäžããããåèè¡å§ã®äœäžãæ¹èµ·ããã
ã®ããå¿èã·ãšãã¯åã³äœè¡å§çã®å Žåã«ã¯ãã
ããã®è¬å€ã®æäžã¯å°é£ã«ãªãã βâã¢ãã¬ããªã³é®æè¬ãã€ã³ãã©ãŒã«
ïŒInderalïŒããã³ãŸãžãã·ã³ïŒBenzodixinïŒããªã¯
ã¹ãã¬ãããŒã«ïŒOxprenololïŒããåãå€ãã®äž
å©ãªå¯äœçšãæããããããã®ååç©ã¯é«ãæ¯æ§
ãæãïŒã€ã³ãã©ãŒã«ã®LD50ã¯ãã¯ã€ãããŠã¹
ã«ã€ããŠ30ã50mgïŒKgã§ããïŒãè² ã®å€åäœçšã
äŸããããããã®è¬å€ã¯ãæŽåŸèãæ¿å®€ç³»é®æã
å¿èæ©èœäžå šãæ°ç®¡æ¯åæ¯ãçæ§ç³å°¿ç åã³ãã
ã«é¡ããçŸæ£ã«ãããŠã¯çŠå¿ã§ããã èžçã®çºäœãé®æããããã«ææ©ç¡é žååç©ã
æå¹ã«äœ¿çšãããŠããããããã®ååç©ã®äžã§ã
ããã°ãªã»ãªã³ãæãå€ã䜿çšãããŠããããã
ãã°ãªã»ãªã³ã¯å åèã®ç·åŒµãæ¹åãããããŠæ«
梢è¡ç®¡ã®æµæã調æŽããããã«ããå¿èã®å€§åè
ãžã®è¡æ¶²æåºæ©èœãå©é·ããã ãããã°ãªã»ãªã³ã®äžå©ãªæ§è³ªã¯ãäœçšæç¶æ
éãçããããããŠãé 骚éèã®ç·åŒµãå€ããŠåŒ·
ãé çãæ¹èµ·ããå¯èœæ§ãããç¹ã§ããã åãå¿èâè¡ç®¡ç³»ã«å¯Ÿããäœçšãå«ãåºç¯ãªç
ç©åŠçäœçšãæãã倩ç¶ä»£è¬ç£ç©ã§ããγâãã
ããã¿ã€ã³ãç¥ãããŠããïŒNature 183ïŒ328ã
1959幎ïŒãããããªããγâããããã¿ã€ã³ã¯ç
ç©äžã§æ¥éã«ä»£è¬ãããŠã«ã«ããã³ã«å€åããã
ããŠããã®ããã«çæéã®å¹æããæããªãã ãã®çºæã¯ãæ¯æ§ãäœããå¹æãé«ãããããŠ
æç¶æéãé·ããããããå ¬ç¥ã®å¿èâè¡ç®¡ç³»çŸ
æ£æ²»ççšè¬ç¹æã®å¯äœçšãæããªãæ°èŠãªå¿èâ
è¡ç®¡ç³»çŸæ£æ²»çè¬ãæäŸããããšãç®çãšããã ãã®çºæã®å»è¬çµæç©ã¯æ°èŠãªãã®ã§ãããã
ã®æè¡åéã«ãããŠç¥ãããŠããªãã çºæè çã¯ãåèšã®ç®çãã次ã®æ§é åŒã ïŒCH3ïŒ3N+NHCH2CH2COO-ã»2H2O ãæãã掻æ§æåïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«
ããã©ãžããŠã ïŒããããªããŒãåã³è¬å€ãšããŠ
蚱容ãããåžéå€ãå«ãã§æãæ°èŠãªå¿èâè¡ç®¡
ç³»çŸæ£æ²»ççšå»è¬çµæç©ã«ããéæããã è¬å€ååç©ã泚å°è¬ãšããŠäœ¿çšããå Žåã«ã¯ã
ãã®æ³šå°è¬ã«ã¯ãïŒééïŒ ã40ééïŒ ã®æŽ»æ§æ
åãåã³å»è¬ãšããŠèš±å®¹ãããåžéå€ãšããŠæº¶å€
ããªãã¡èžçæ°Žåã¯ç匵液ãå«æããããã é å€åã¯ã«ãã»ã«å€ãšããŠæäžããå Žåã«ã¯ã
ïŒé å€åã¯ã«ãã»ã«å€äžã«0.1ã0.5ïœã®æŽ»æ§æå
ãå«æããããã ç¹å¥ã®å®éšçç 究ã«ããããã®è¬å€ã®å¹æã¯ã
å åèãæ¡åŒµããå¿çå±€ã«ããããšãã«ã®ãŒäŸäž
ç©è³ªã®ååãä¿é²ãããããŠå¿ç现èã®ããã³ã³
ããªã¢ç³»åšç®¡ã«ç©æ¥µçäœçšãäŸããããã«ããæ
çµçã«ã¯å¿çã®ç©æ¥µçå€åäœçšã®é¡èãªå¢å ã«å¯
äžãããšããæ§è³ªã«åºããŠããããšãæããã«ãª
ã€ãã ãã®çºæã®å»è¬è£œåã¯ãå¿èæ©èœäžå šãåŒæ¬
æãå¿ççãå¿è硬åçãèè¡æ§å¿çŸæ£ãåçš®ã®
åå ã«ããäžæŽèã®ããšãçŸæ£ã®æ²»çã«æçšã§ã
ãããããã®çäŸã«ãããŠããã®çºæã®è¬å€ã®æ²»
çå¹æã¯ãäŸãã°åŒ·å¿é ç³äœãβâé®æå€ãã«ã«
ãã¯ãã¡ã³ïŒCarbocromeneïŒãå«ãä»ã®è¬å€ã®
æ²»çå¹ææ¯ã¹ãŠåè¶ããŠããããªãŠããæ§åŒæ¬ æ
ã«ãããæ ¢æ§ä»£åäžå šãå¿çæ¢å¡ã«ãããæ¥æ§åŸª
ç°æ©èœäžå šã®çäŸã«ãããŠãç¹ã«é¡èãªæ²»çå¹æ
ã芳å¯ããããåãçºäœæ§é »æ¶ã现åãâé®
æãçæ£ã®çäŸã«ãããŠãã®çºæã®å»è¬ãæäžã
ãå Žåãé¡èã§ã¯ãªããç©æ¥µçå¹æã芳å¯ãã
ãããã®çºæã®è¬å€ã¯ãåç©å®éšåã³çš®ã ã®ç æ°
ã®æ£è ã«å¯Ÿããèšåºè©Šéšã«ããè©Šéšãããã ããªãã¡ããã®çºæã®è¬å€ã®å¹æããå¡©åã«ã«
ã·ãŠã ã®äžæŽèçºçæäžéåã³èŽæ»æäžéã®å€å
ãšé¢é£ãããŠèª¿ã¹ããè©Šéšã¯ããŠã¬ã¿ã³éº»é ãã
äœé19ã28ïœã®ãã¯ã€ãããŠã¹ïŒéåã³éïŒã䜿
çšããèžå»çµç±èªå°ã«ããECGïŒå¿é»å³ïŒãæ¡
ã€ããïŒïŒ å¡©åã«ã«ã·ãŠã 溶液ããäžå®é床ïŒ15
ç§éã«0.1mlïŒã§å®éšåç©ã®å°Ÿéèã«æäžããã
äžæŽèåã³å¿èåæ¢ãæ¹èµ·ããå¡©åã«ã«ã·ãŠã ã®
å¹³åæäžéã枬å®ãããè©ŠéšçŸ€ã«ãããŠãå¡©åã«
ã«ã·ãŠã ã®æäžéå§å45åã60åã120åã180å
åã³240åã«è¢«æ€ååç©ãæäžããïŒç¬¬ïŒè¡šïŒãïŒ
âïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠã ïŒã
ãããªããŒãã掻æ§æåãšããè¬å€ãè ¹è å ã«ïŒ
åäºåæäžããã ãã§å¡©åã«ã«ã·ãŠã ã®äžæŽèçº
çæäžéåã³èŽæ»æäžéãå¢å ãããå è¡æè¡ã®
è¬å€ã§ããããã«ã€ã³ã¢ããåã³ãããžã³ã¯é©åœ
ãªæäžéã«ãããŠãã®çºæã®è¬å€ã«æ¯ã¹ãŠé¡èãª
å¡©åã«ã«ã·ãŠã ã®äžæŽèçºçæäžéã®å¢å ãäŸã
ããããã®çºæã®è¬å€ã¯ãå è¡æè¡ã®è¬å€ã«æ¯ã¹
ãŠãããäœãæ¯æ§ã«ãããŠããé·ãæäžæŽèäœçš
ãçºæ®ããïŒç¬¬ïŒè¡šïŒã ãŠã¬ã¿ã³éº»é ããäœé190ã230ïœã®ãã¯ã€ãã©
ããïŒéåã³éïŒã䜿çšããŠæäžæŽèäœçšãè©Šéš
ãããããã®åç©ã®ECGïŒå¿é»å³ïŒãèšé²ã
ããã©ããã®å€§è ¿ã®éèã«äžå®é床ã§ã¢ã³ããã³
ãå°å ¥ãããããŠããã®çºæã®è¬å€ã®ä¿è·å¹æã®
äžã§ã¢ã³ããã³ã®äžæŽèçºçæäžéåã³èŽæ»æäž
éã®å€åã枬å®ããããã®çºæã®è¬å€ã¯çµå£æäž
ã«ãã€ãŠãé¡èãªä¿è·å¹æãæããããšãèŠåºã
ãïŒç¬¬ïŒè¡šïŒã ããªãã¡ããã®çºæã®è¬å€ãæ¥çšé25mgïŒKgã§
ïŒé±éã«ãããäºé²ççµå£æäžãããã®æçµæäž
åŸïŒãïŒæéã«ã¢ã³ããã³ã泚å°ãããšãããã¢
ã³ããã³ã®äžæŽèçºçæäžéåã³èŽæ»æäžéã¯å®
質äžïŒãããã38.7ïŒ åã³27.6ïŒ ïŒå¢å ãããã
ãã«é·æéã«ããã€ãŠæäžããå Žåãè¬å€ã®ä¿è·
äœçšã¯ããã«æçœã«ãªã€ãïŒç¬¬ïŒè¡šïŒã äœé0.3ã0.6Kgã®éåã³éã®å®¶å ã®è³ä»åšçžã®
éèã«æäžé60ÎŒïœïŒKgã§ã¹ãããã³ãã³ïŒ§ãæ
äžããããã«ãå®å®ããå¿å®€æå€åçž®ãçºçãã
ãŸã§ïŒã10åéããšã«ïŒã10ÎŒïœïŒKgã®åèšç©è³ª
ãæäžããããšã«ãããã¹ãããã³ãã³ïŒ§ã®äžæŽ
èçºçæäžéã®å€åã«å¯Ÿãããã®çºæã®è¬å€ã®å¹
æãè©Šéšãããè©ŠéšçŸ€ã«ã€ããåèšé ç³äœæäžå
20ã30åã«ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©
ãžããŠã ïŒããããªããŒãã®æº¶æ¶²ãéèå ã«äºé²
æäžããæšæºèªå°ã«ããECGãèšé²ããã è¬å€ã10mgïŒKgæäžããããšã«ããã¹ãããã³
ãã³ïŒ§ã®äžæŽèçºçæäžéã67±ïŒÎŒïœïŒKgãã
90±15ÎŒïŒKgã«å¢å ããããšãèŠåºããïŒç¬¬ïŒ
è¡šïŒããã®çºæã®è¬å€ã®æäžéãããã«å¢å ãã
ããšã«ããããã®è¬å€ã®ä¿è·å¹æãå¢å ããã
æã«ãããå¿èæ©èœäžå šãåçš®ã®åå ããçãã
äžæŽèã®ããšãå¿èâè¡ç®¡ç³»çŸæ£ã®æ²»ççšå»è¬çµ
æç©ã«é¢ããã çŸåšãäž»èŠãªéžæç匷å¿è¬è£œå€ã¯åŒ·å¿é ç³äœã§
ããããã®åŒ·å¿é ç³äœè£œå€ã«ã¯ããªãã³è£œå€ãã¹
ãããã¢ã³ãã¹è£œå€ãããçš®ã®çŸåããåŸããã
補å€ãšå ±ã«ãžãã¿ãªã¹è£œå€ãå«ãŸããïŒïŒã»
Yuã»MashkovskyïŒPharmaceutical
PreparationïŒM.ïŒMeditsina Publishing
HouseïŒ1977幎ãåç §ïŒã é ç³äœã®åºæ¬çãªæ¬ ç¹ã¯æ²»çææ°ãäœãç¹ã§ã
ããåããã®è£œå€ã®éå°æäžã«ããé倧ãªå䜵
çãããªãã¡ãæ¥æ§åŸèãé »çºæå€åçž®ãäºæ®µ
èãäžæ®µèãæ¿å®€ç³»äŒå°ã®æžéãå¿å®€æ§ç²ååã³
æ¡åŒµæå¿æ¶ååæ¢ãæ¹èµ·ãããã å¿ ç¶çãªæ¬ ç¹ã¯ãããã«ãè¬å€ã®è¡äžæ¿åºŠãšæ²»
çå¹æãšã®éã«çŽæ¥é¢ä¿ããªãããšã§ããããã®
ãããé ç³äœã¯ãã°ãã°ãèç²èãåºæ¿ããåå
äžæ¢ã«äœçšããŠæ¶ç«äžè¯ãæ¹èµ·ããã å¿èçŸæ£æ²»ççšè£œå€ã®å€ãã¯æäžè補å€ã§ã
ãããããã®å æãåºã䜿çšãããŠãããã®ã®ïŒ
ã€ã«ããã«ã€ã³ã¢ãããããããã®è¬åã¯æå€å
çž®ãå«ãçš®ã ã®äžæŽèã«å¯ŸããŠæå¹ã«é©çšãããŠ
ãããããããªãããã®è¬å€ãå¯äœçšãããªã
ã¡ãå šèº«è¡°åŒ±ãé çãåæ°ãååãäžç çãæ¶ç«
äžè¯çç¶ãæ¹èšãããããŠéèæäžããå Žåã«ã¯
å¿èã·ãšãã¯ãèµ·ããå¯èœæ§ãããããã®äžãå¿
çæ¢å¡ã®çäŸã«ãããŠã¯ãå¿çåçž®é»å®³åã³åè
è¡å§ã®äœäžãèµ·ããå¯èœæ§ããããããéåžžã«æ
éã«æäžããªããã°ãªããªãã å¹æã®é«ãè¬å€ã§ããã¢ã€ããªã³ïŒAimalinïŒ
åã³ãšãœã¢ãã³ãïŒâã«ã«ããã³é ž10âïŒïŒâã¢
ãŒããªã«ããããªãã«ïŒããšããã¢ãžããããã¯
ããªãã®ãšãã«ãšã¹ãã«ãããæ¬è³ªçã«åæ§ã®æ¬
ç¹ãæããŠããããããã®è¬å€ã¯ããã«å¿çã®å
çž®æ§ãäœäžããããåèè¡å§ã®äœäžãæ¹èµ·ããã
ã®ããå¿èã·ãšãã¯åã³äœè¡å§çã®å Žåã«ã¯ãã
ããã®è¬å€ã®æäžã¯å°é£ã«ãªãã βâã¢ãã¬ããªã³é®æè¬ãã€ã³ãã©ãŒã«
ïŒInderalïŒããã³ãŸãžãã·ã³ïŒBenzodixinïŒããªã¯
ã¹ãã¬ãããŒã«ïŒOxprenololïŒããåãå€ãã®äž
å©ãªå¯äœçšãæããããããã®ååç©ã¯é«ãæ¯æ§
ãæãïŒã€ã³ãã©ãŒã«ã®LD50ã¯ãã¯ã€ãããŠã¹
ã«ã€ããŠ30ã50mgïŒKgã§ããïŒãè² ã®å€åäœçšã
äŸããããããã®è¬å€ã¯ãæŽåŸèãæ¿å®€ç³»é®æã
å¿èæ©èœäžå šãæ°ç®¡æ¯åæ¯ãçæ§ç³å°¿ç åã³ãã
ã«é¡ããçŸæ£ã«ãããŠã¯çŠå¿ã§ããã èžçã®çºäœãé®æããããã«ææ©ç¡é žååç©ã
æå¹ã«äœ¿çšãããŠããããããã®ååç©ã®äžã§ã
ããã°ãªã»ãªã³ãæãå€ã䜿çšãããŠããããã
ãã°ãªã»ãªã³ã¯å åèã®ç·åŒµãæ¹åãããããŠæ«
梢è¡ç®¡ã®æµæã調æŽããããã«ããå¿èã®å€§åè
ãžã®è¡æ¶²æåºæ©èœãå©é·ããã ãããã°ãªã»ãªã³ã®äžå©ãªæ§è³ªã¯ãäœçšæç¶æ
éãçããããããŠãé 骚éèã®ç·åŒµãå€ããŠåŒ·
ãé çãæ¹èµ·ããå¯èœæ§ãããç¹ã§ããã åãå¿èâè¡ç®¡ç³»ã«å¯Ÿããäœçšãå«ãåºç¯ãªç
ç©åŠçäœçšãæãã倩ç¶ä»£è¬ç£ç©ã§ããγâãã
ããã¿ã€ã³ãç¥ãããŠããïŒNature 183ïŒ328ã
1959幎ïŒãããããªããγâããããã¿ã€ã³ã¯ç
ç©äžã§æ¥éã«ä»£è¬ãããŠã«ã«ããã³ã«å€åããã
ããŠããã®ããã«çæéã®å¹æããæããªãã ãã®çºæã¯ãæ¯æ§ãäœããå¹æãé«ãããããŠ
æç¶æéãé·ããããããå ¬ç¥ã®å¿èâè¡ç®¡ç³»çŸ
æ£æ²»ççšè¬ç¹æã®å¯äœçšãæããªãæ°èŠãªå¿èâ
è¡ç®¡ç³»çŸæ£æ²»çè¬ãæäŸããããšãç®çãšããã ãã®çºæã®å»è¬çµæç©ã¯æ°èŠãªãã®ã§ãããã
ã®æè¡åéã«ãããŠç¥ãããŠããªãã çºæè çã¯ãåèšã®ç®çãã次ã®æ§é åŒã ïŒCH3ïŒ3N+NHCH2CH2COO-ã»2H2O ãæãã掻æ§æåïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«
ããã©ãžããŠã ïŒããããªããŒãåã³è¬å€ãšããŠ
蚱容ãããåžéå€ãå«ãã§æãæ°èŠãªå¿èâè¡ç®¡
ç³»çŸæ£æ²»ççšå»è¬çµæç©ã«ããéæããã è¬å€ååç©ã泚å°è¬ãšããŠäœ¿çšããå Žåã«ã¯ã
ãã®æ³šå°è¬ã«ã¯ãïŒééïŒ ã40ééïŒ ã®æŽ»æ§æ
åãåã³å»è¬ãšããŠèš±å®¹ãããåžéå€ãšããŠæº¶å€
ããªãã¡èžçæ°Žåã¯ç匵液ãå«æããããã é å€åã¯ã«ãã»ã«å€ãšããŠæäžããå Žåã«ã¯ã
ïŒé å€åã¯ã«ãã»ã«å€äžã«0.1ã0.5ïœã®æŽ»æ§æå
ãå«æããããã ç¹å¥ã®å®éšçç 究ã«ããããã®è¬å€ã®å¹æã¯ã
å åèãæ¡åŒµããå¿çå±€ã«ããããšãã«ã®ãŒäŸäž
ç©è³ªã®ååãä¿é²ãããããŠå¿ç现èã®ããã³ã³
ããªã¢ç³»åšç®¡ã«ç©æ¥µçäœçšãäŸããããã«ããæ
çµçã«ã¯å¿çã®ç©æ¥µçå€åäœçšã®é¡èãªå¢å ã«å¯
äžãããšããæ§è³ªã«åºããŠããããšãæããã«ãª
ã€ãã ãã®çºæã®å»è¬è£œåã¯ãå¿èæ©èœäžå šãåŒæ¬
æãå¿ççãå¿è硬åçãèè¡æ§å¿çŸæ£ãåçš®ã®
åå ã«ããäžæŽèã®ããšãçŸæ£ã®æ²»çã«æçšã§ã
ãããããã®çäŸã«ãããŠããã®çºæã®è¬å€ã®æ²»
çå¹æã¯ãäŸãã°åŒ·å¿é ç³äœãβâé®æå€ãã«ã«
ãã¯ãã¡ã³ïŒCarbocromeneïŒãå«ãä»ã®è¬å€ã®
æ²»çå¹ææ¯ã¹ãŠåè¶ããŠããããªãŠããæ§åŒæ¬ æ
ã«ãããæ ¢æ§ä»£åäžå šãå¿çæ¢å¡ã«ãããæ¥æ§åŸª
ç°æ©èœäžå šã®çäŸã«ãããŠãç¹ã«é¡èãªæ²»çå¹æ
ã芳å¯ããããåãçºäœæ§é »æ¶ã现åãâé®
æãçæ£ã®çäŸã«ãããŠãã®çºæã®å»è¬ãæäžã
ãå Žåãé¡èã§ã¯ãªããç©æ¥µçå¹æã芳å¯ãã
ãããã®çºæã®è¬å€ã¯ãåç©å®éšåã³çš®ã ã®ç æ°
ã®æ£è ã«å¯Ÿããèšåºè©Šéšã«ããè©Šéšãããã ããªãã¡ããã®çºæã®è¬å€ã®å¹æããå¡©åã«ã«
ã·ãŠã ã®äžæŽèçºçæäžéåã³èŽæ»æäžéã®å€å
ãšé¢é£ãããŠèª¿ã¹ããè©Šéšã¯ããŠã¬ã¿ã³éº»é ãã
äœé19ã28ïœã®ãã¯ã€ãããŠã¹ïŒéåã³éïŒã䜿
çšããèžå»çµç±èªå°ã«ããECGïŒå¿é»å³ïŒãæ¡
ã€ããïŒïŒ å¡©åã«ã«ã·ãŠã 溶液ããäžå®é床ïŒ15
ç§éã«0.1mlïŒã§å®éšåç©ã®å°Ÿéèã«æäžããã
äžæŽèåã³å¿èåæ¢ãæ¹èµ·ããå¡©åã«ã«ã·ãŠã ã®
å¹³åæäžéã枬å®ãããè©ŠéšçŸ€ã«ãããŠãå¡©åã«
ã«ã·ãŠã ã®æäžéå§å45åã60åã120åã180å
åã³240åã«è¢«æ€ååç©ãæäžããïŒç¬¬ïŒè¡šïŒãïŒ
âïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠã ïŒã
ãããªããŒãã掻æ§æåãšããè¬å€ãè ¹è å ã«ïŒ
åäºåæäžããã ãã§å¡©åã«ã«ã·ãŠã ã®äžæŽèçº
çæäžéåã³èŽæ»æäžéãå¢å ãããå è¡æè¡ã®
è¬å€ã§ããããã«ã€ã³ã¢ããåã³ãããžã³ã¯é©åœ
ãªæäžéã«ãããŠãã®çºæã®è¬å€ã«æ¯ã¹ãŠé¡èãª
å¡©åã«ã«ã·ãŠã ã®äžæŽèçºçæäžéã®å¢å ãäŸã
ããããã®çºæã®è¬å€ã¯ãå è¡æè¡ã®è¬å€ã«æ¯ã¹
ãŠãããäœãæ¯æ§ã«ãããŠããé·ãæäžæŽèäœçš
ãçºæ®ããïŒç¬¬ïŒè¡šïŒã ãŠã¬ã¿ã³éº»é ããäœé190ã230ïœã®ãã¯ã€ãã©
ããïŒéåã³éïŒã䜿çšããŠæäžæŽèäœçšãè©Šéš
ãããããã®åç©ã®ECGïŒå¿é»å³ïŒãèšé²ã
ããã©ããã®å€§è ¿ã®éèã«äžå®é床ã§ã¢ã³ããã³
ãå°å ¥ãããããŠããã®çºæã®è¬å€ã®ä¿è·å¹æã®
äžã§ã¢ã³ããã³ã®äžæŽèçºçæäžéåã³èŽæ»æäž
éã®å€åã枬å®ããããã®çºæã®è¬å€ã¯çµå£æäž
ã«ãã€ãŠãé¡èãªä¿è·å¹æãæããããšãèŠåºã
ãïŒç¬¬ïŒè¡šïŒã ããªãã¡ããã®çºæã®è¬å€ãæ¥çšé25mgïŒKgã§
ïŒé±éã«ãããäºé²ççµå£æäžãããã®æçµæäž
åŸïŒãïŒæéã«ã¢ã³ããã³ã泚å°ãããšãããã¢
ã³ããã³ã®äžæŽèçºçæäžéåã³èŽæ»æäžéã¯å®
質äžïŒãããã38.7ïŒ åã³27.6ïŒ ïŒå¢å ãããã
ãã«é·æéã«ããã€ãŠæäžããå Žåãè¬å€ã®ä¿è·
äœçšã¯ããã«æçœã«ãªã€ãïŒç¬¬ïŒè¡šïŒã äœé0.3ã0.6Kgã®éåã³éã®å®¶å ã®è³ä»åšçžã®
éèã«æäžé60ÎŒïœïŒKgã§ã¹ãããã³ãã³ïŒ§ãæ
äžããããã«ãå®å®ããå¿å®€æå€åçž®ãçºçãã
ãŸã§ïŒã10åéããšã«ïŒã10ÎŒïœïŒKgã®åèšç©è³ª
ãæäžããããšã«ãããã¹ãããã³ãã³ïŒ§ã®äžæŽ
èçºçæäžéã®å€åã«å¯Ÿãããã®çºæã®è¬å€ã®å¹
æãè©Šéšãããè©ŠéšçŸ€ã«ã€ããåèšé ç³äœæäžå
20ã30åã«ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©
ãžããŠã ïŒããããªããŒãã®æº¶æ¶²ãéèå ã«äºé²
æäžããæšæºèªå°ã«ããECGãèšé²ããã è¬å€ã10mgïŒKgæäžããããšã«ããã¹ãããã³
ãã³ïŒ§ã®äžæŽèçºçæäžéã67±ïŒÎŒïœïŒKgãã
90±15ÎŒïŒKgã«å¢å ããããšãèŠåºããïŒç¬¬ïŒ
è¡šïŒããã®çºæã®è¬å€ã®æäžéãããã«å¢å ãã
ããšã«ããããã®è¬å€ã®ä¿è·å¹æãå¢å ããã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ã¹ãããã³ãã³äžæŽèã«å¯Ÿãããã®çºæã®è¬å€
ã®æ²»çå¹æã調ã¹ãããã«ãåèšä»¥å€ã®äžé£ã®è©Š
éšãè¡ã€ãã äœé3.0ã3.8Kgã®å®¶å ïŒéåã³éïŒã«ã40ã60
å以å ã«äžæŽèãæ¹èµ·ããå ±éã®æäžé80ÎŒïœïŒ
Kgã§ãã¹ãããã³ãã³ãéèå æäžãããäžéè
ãæããè©ŠéšçŸ€ã«ã被æ€è¬å€ãéèå æäžããã ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠ
ã ïŒããããªããŒãã掻æ§æåãšããè¬å€ãïŒã
ïŒmgïŒKgæäžãããšãããå€ãã®è©Šéšã«ãããŠã
éèå æäžåŸïŒãïŒåéã®å ã«ãã¹ãããã³ãã³
ã«ããæ¹èµ·ããã家å ã®å¿å®€æ¥æ§äžæŽèãäžæ
çã«åæ¢ããããšãèŠåºããããQRSTã³ã³ãã¬
ãã¯ã¹ã®å€åãæžå°ãããè¬å€ãïŒmgïŒKgã®æäž
éã§æäžããåŸãèŠåçæŽåŸåãå¹³å12±ïŒåé
ç¶ãããã®åŸåã ã«äžæŽèãåçºããããè¬å€ã
å床ïŒãïŒmgïŒKgæäžããããšã«ãã€ãŠäžæŽèã¯
åã³æ¶å€±ããããã®å ŽåæŽåŸåã¯15ã30åéç¶ç¶
ãããããŠãå€ãã®è©Šéšã«ãããŠäžæŽèã¯ãã¯ã
åçºããªãã€ããããã«ãå šæäžé500ÎŒïœïŒKg
ã®ã¹ãããã³ãã³ïŒ«ãå€§è ¿éèã«æäžããäœé
600ã710Kgã®éº»é ããããã¢ã«ã¢ãããçšããŠè©Š
éšãè¡ã€ãã ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãŸããŠ
ã ïŒããããªããŒãã掻æ§æåãšããè¬å€ããäž
éèãæããè©ŠéšçŸ€ã«å¯ŸããŠéèå æäžããã被
æ€è¬å€ãéèå æäžããåŸïŒãïŒåé以å ã«ãã¹
ãããã³ãã³ïŒ«ã«ããæ¹èµ·ãããå¿å®€æ§äžéèã¯
äžæçã«åæ¢ããããšãèŠåºãããQRSTã³ã³ã
ã¬ãã¯ã¹ã®å€åã¯æžå°ãããããŠãå¿æ¿æ§çŽ°åã
æ¶å€±ããããã®ããšã¯ãâå°æ³¢ã®åºçŸã«ãã瀺
ããããïŒãïŒmgïŒKgã®è¬å€ãé©æã«æäžãã幟
ã€ãã®å Žåã«ã¯ãã¹ãããã³ãã³ïŒ«ã«ãã€ãŠæ¹èµ·
ãããæ¿å®€ç³»é®æã解é€ããããšãå¯èœã§ãã€
ãã ããã«ããã®çºæã®è¬å€ã®æ¯æäžæŽèå¹æåã³
æ¯æã¢ã³ã®ãå¹æã«ã€ããŠè©Šéšãããæ¯èŒã®ãã
ã«ãå è¡æè¡ã®æäžéèè¬å€ããªãã¡ãããžã³ã
ããã«ã€ã³ã¢ããããªãã«ã€ã³åã³å ¬ç¥ã®æã¢ã³
ã®ãå€ããªãã¡ã«ã«ãã¯ãã¡ã³ã«ã€ããŠãè©Šéšã
ãããã®çºæã®æ°èŠãªå»è¬çµæç©ã®å¹æãäœé
2.9ã3.6Kgã®ãã³ãçšããŠè©Šéšãããå¿æ¿åã³å¿
宀ã®é»æ°ç现åã®éŸå€ã枬å®ããããã«ãè¬å€ã
ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠã ïŒ
ããããªããŒãã®10ïŒ æ°Žæº¶æ¶²ãšããŠäœ¿çšãããèž
å»åã³å¿èãåéããåŸäººå·¥åŒåžãæœããªããå³
å¿æ¿åã³å·Šå¿å®€ã®é 端ã«éç¶é»æ¥µãé©çšããã
1mã»ïœã®æ¹åœ¢ãã«ã¹ã«ããæ¯ç§15åã®åºæ¿ãäž
ãããå¿èãæµéããé»æµãã现åãçŸããããŸ
ã§åŸã ã«å¢å ããããã®çŽ°åã¯ãECGåã³ãã«
ã³ã»ããªã»ã·ã¹ãã ïŒNarco Bio SystemsïŒç€Ÿè£œ
ã®ãã€ãžãªã°ã©ãã«ãã枬å®ããåèè¡å§ã«ãã
æ€ç¥ããã被æ€ååç©ã¯éèå ã«æäžãããçµæ
ã第ïŒè¡šã«ç€ºãããã®çºæã®å»è¬çµæç©ãæäžé
ïŒã15mgïŒKgã§éèå æäžãããšãããå¿æ¿åã³
å¿å®€ã®é»æ°ç现åã®éŸå€ã40ã55ïŒ äžæãããã
ã«ã€ã³ã¢ããã¯40ã55mgïŒâã®æäžéã«ãããŠã
ããšåãéŸå€ã瀺ãããããžã³åã³ãªãã«ã€ã³ã¯
ããã«äœãæäžéã§ããé«ãå¹æãçºæ®ãããã
å®è³ªäžããã«é«ãæ¯æ§ã瀺ããã è¬å€ãæ¯èŒãããããæ²»çå¹æã®ç¯å²ã®èŠæºãš
ããŠåæ°èŽæ»æäžéãšåæ°å¹ææäžéãšã®æ¯
ïŒLD50ïŒED50ïŒã䜿çšãããããæäžæŽèææ°ãš
ãããïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžã
ãŠã ïŒããããªããŒãã掻æ§æåãšããŠ10ïŒ å«ã
溶液ã®åœ¢ã«ãããã®çºæã®å»è¬çµæç©ã®ãã®ç¹å®
ã®ã¿ã€ãã®äžéèã«ã€ããŠã®æäžéèææ°
ïŒ443ïŒã¯ããããžã³ïŒ26ïŒããªãã«ã€ã³ïŒ13ïŒå
ã³ããã«ã€ã³ã¢ããïŒ2.3ïŒã®æäžæŽèææ°ãã
å®è³ªäžé«ãã€ããã¢ã³ããã³ã«ããæ¹èµ·ããäžæŽ
èèåã䜿çšããå»è¬è£œå€ã®æäžæŽèäœçšã®æ¯èŒ
è©Šéšããäœé190ã240ïœã®ãã¯ã€ãã©ããã䜿çš
ããŠè¡ã€ãã被æ€è¬å€ããã¢ã³ããã³æäžã®10ã
40ååã«è ¹è å æäžãããçµæã第ïŒè¡šã«ç€ºãã ãã®äžæŽèã¢ãã«ã«ãããŠããã®çºæã®å»è¬è£œ
å€ã¯ãå ¬ç¥ã®æäžæŽèå€ã«æ¯ã¹ãŠå®è³ªäžé«ãå¹æ
ã瀺ãããããªãã¡ããã®çºæã®å»è¬è£œå€ã®æäž
æŽèææ°ã¯354ã§ãããä»æ¹ããããžã³åã³ãã
ã«ã€ã³ã¢ããã®ããã¯ããããã16åã³2.5ã§ã
ã€ããäžæŽèã®ç¬¬äžã®ã¢ãã«ãšããŠã¢ã«ã¢ããã®
ã¹ãããã³ãã³äžæŽèã䜿çšãããäœé420ã710
ïœã®ã¢ã«ã¢ããã«450ÎŒïœïŒKgã®ã¹ãããã³ãã³
ãæäžãããå¯Ÿç §çŸ€ã«ãããŠã¯ãåèšã®éã®ã¹
ãããã³ãã³ã®æäžã«ããäžæŽèçç¶ãçããã
ããŠ12ã20åé以å ã«åç©ãæ»ãã ãäžæŽèãæ
ããåç©ã«å¯ŸããŠè¢«æ€è¬å€ãéèå æäžãããã
ã®çµæã第ïŒè¡šã«ç€ºãããã®è©Šéšã«ããããã®çº
æã®å»è¬çµæç©åã³ããã«ã€ã³ã¢ãããéèå æ
äžããå ŽåãïŒåç©äžïŒåç©ã«ãããŠïŒã20éã«
ãããã¢ã«ã¢ããã®ã¹ãããã³ãã³èªå°äžæŽèã
äžæçã«é®æãããä»æ¹ããªãã«ã€ã³åã³ãããž
ã³ãæäžããå ŽåãããããïŒåç©äžïŒåç©åã³
ïŒåç©äžïŒåç©ã«ãããŠããã0.5ãïŒåéã«ã
ããçç¶ãæ¹åãããããšããECGã®ããŒã¿ã
ã瀺ãããã
ã®æ²»çå¹æã調ã¹ãããã«ãåèšä»¥å€ã®äžé£ã®è©Š
éšãè¡ã€ãã äœé3.0ã3.8Kgã®å®¶å ïŒéåã³éïŒã«ã40ã60
å以å ã«äžæŽèãæ¹èµ·ããå ±éã®æäžé80ÎŒïœïŒ
Kgã§ãã¹ãããã³ãã³ãéèå æäžãããäžéè
ãæããè©ŠéšçŸ€ã«ã被æ€è¬å€ãéèå æäžããã ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠ
ã ïŒããããªããŒãã掻æ§æåãšããè¬å€ãïŒã
ïŒmgïŒKgæäžãããšãããå€ãã®è©Šéšã«ãããŠã
éèå æäžåŸïŒãïŒåéã®å ã«ãã¹ãããã³ãã³
ã«ããæ¹èµ·ããã家å ã®å¿å®€æ¥æ§äžæŽèãäžæ
çã«åæ¢ããããšãèŠåºããããQRSTã³ã³ãã¬
ãã¯ã¹ã®å€åãæžå°ãããè¬å€ãïŒmgïŒKgã®æäž
éã§æäžããåŸãèŠåçæŽåŸåãå¹³å12±ïŒåé
ç¶ãããã®åŸåã ã«äžæŽèãåçºããããè¬å€ã
å床ïŒãïŒmgïŒKgæäžããããšã«ãã€ãŠäžæŽèã¯
åã³æ¶å€±ããããã®å ŽåæŽåŸåã¯15ã30åéç¶ç¶
ãããããŠãå€ãã®è©Šéšã«ãããŠäžæŽèã¯ãã¯ã
åçºããªãã€ããããã«ãå šæäžé500ÎŒïœïŒKg
ã®ã¹ãããã³ãã³ïŒ«ãå€§è ¿éèã«æäžããäœé
600ã710Kgã®éº»é ããããã¢ã«ã¢ãããçšããŠè©Š
éšãè¡ã€ãã ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãŸããŠ
ã ïŒããããªããŒãã掻æ§æåãšããè¬å€ããäž
éèãæããè©ŠéšçŸ€ã«å¯ŸããŠéèå æäžããã被
æ€è¬å€ãéèå æäžããåŸïŒãïŒåé以å ã«ãã¹
ãããã³ãã³ïŒ«ã«ããæ¹èµ·ãããå¿å®€æ§äžéèã¯
äžæçã«åæ¢ããããšãèŠåºãããQRSTã³ã³ã
ã¬ãã¯ã¹ã®å€åã¯æžå°ãããããŠãå¿æ¿æ§çŽ°åã
æ¶å€±ããããã®ããšã¯ãâå°æ³¢ã®åºçŸã«ãã瀺
ããããïŒãïŒmgïŒKgã®è¬å€ãé©æã«æäžãã幟
ã€ãã®å Žåã«ã¯ãã¹ãããã³ãã³ïŒ«ã«ãã€ãŠæ¹èµ·
ãããæ¿å®€ç³»é®æã解é€ããããšãå¯èœã§ãã€
ãã ããã«ããã®çºæã®è¬å€ã®æ¯æäžæŽèå¹æåã³
æ¯æã¢ã³ã®ãå¹æã«ã€ããŠè©Šéšãããæ¯èŒã®ãã
ã«ãå è¡æè¡ã®æäžéèè¬å€ããªãã¡ãããžã³ã
ããã«ã€ã³ã¢ããããªãã«ã€ã³åã³å ¬ç¥ã®æã¢ã³
ã®ãå€ããªãã¡ã«ã«ãã¯ãã¡ã³ã«ã€ããŠãè©Šéšã
ãããã®çºæã®æ°èŠãªå»è¬çµæç©ã®å¹æãäœé
2.9ã3.6Kgã®ãã³ãçšããŠè©Šéšãããå¿æ¿åã³å¿
宀ã®é»æ°ç现åã®éŸå€ã枬å®ããããã«ãè¬å€ã
ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠã ïŒ
ããããªããŒãã®10ïŒ æ°Žæº¶æ¶²ãšããŠäœ¿çšãããèž
å»åã³å¿èãåéããåŸäººå·¥åŒåžãæœããªããå³
å¿æ¿åã³å·Šå¿å®€ã®é 端ã«éç¶é»æ¥µãé©çšããã
1mã»ïœã®æ¹åœ¢ãã«ã¹ã«ããæ¯ç§15åã®åºæ¿ãäž
ãããå¿èãæµéããé»æµãã现åãçŸããããŸ
ã§åŸã ã«å¢å ããããã®çŽ°åã¯ãECGåã³ãã«
ã³ã»ããªã»ã·ã¹ãã ïŒNarco Bio SystemsïŒç€Ÿè£œ
ã®ãã€ãžãªã°ã©ãã«ãã枬å®ããåèè¡å§ã«ãã
æ€ç¥ããã被æ€ååç©ã¯éèå ã«æäžãããçµæ
ã第ïŒè¡šã«ç€ºãããã®çºæã®å»è¬çµæç©ãæäžé
ïŒã15mgïŒKgã§éèå æäžãããšãããå¿æ¿åã³
å¿å®€ã®é»æ°ç现åã®éŸå€ã40ã55ïŒ äžæãããã
ã«ã€ã³ã¢ããã¯40ã55mgïŒâã®æäžéã«ãããŠã
ããšåãéŸå€ã瀺ãããããžã³åã³ãªãã«ã€ã³ã¯
ããã«äœãæäžéã§ããé«ãå¹æãçºæ®ãããã
å®è³ªäžããã«é«ãæ¯æ§ã瀺ããã è¬å€ãæ¯èŒãããããæ²»çå¹æã®ç¯å²ã®èŠæºãš
ããŠåæ°èŽæ»æäžéãšåæ°å¹ææäžéãšã®æ¯
ïŒLD50ïŒED50ïŒã䜿çšãããããæäžæŽèææ°ãš
ãããïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžã
ãŠã ïŒããããªããŒãã掻æ§æåãšããŠ10ïŒ å«ã
溶液ã®åœ¢ã«ãããã®çºæã®å»è¬çµæç©ã®ãã®ç¹å®
ã®ã¿ã€ãã®äžéèã«ã€ããŠã®æäžéèææ°
ïŒ443ïŒã¯ããããžã³ïŒ26ïŒããªãã«ã€ã³ïŒ13ïŒå
ã³ããã«ã€ã³ã¢ããïŒ2.3ïŒã®æäžæŽèææ°ãã
å®è³ªäžé«ãã€ããã¢ã³ããã³ã«ããæ¹èµ·ããäžæŽ
èèåã䜿çšããå»è¬è£œå€ã®æäžæŽèäœçšã®æ¯èŒ
è©Šéšããäœé190ã240ïœã®ãã¯ã€ãã©ããã䜿çš
ããŠè¡ã€ãã被æ€è¬å€ããã¢ã³ããã³æäžã®10ã
40ååã«è ¹è å æäžãããçµæã第ïŒè¡šã«ç€ºãã ãã®äžæŽèã¢ãã«ã«ãããŠããã®çºæã®å»è¬è£œ
å€ã¯ãå ¬ç¥ã®æäžæŽèå€ã«æ¯ã¹ãŠå®è³ªäžé«ãå¹æ
ã瀺ãããããªãã¡ããã®çºæã®å»è¬è£œå€ã®æäž
æŽèææ°ã¯354ã§ãããä»æ¹ããããžã³åã³ãã
ã«ã€ã³ã¢ããã®ããã¯ããããã16åã³2.5ã§ã
ã€ããäžæŽèã®ç¬¬äžã®ã¢ãã«ãšããŠã¢ã«ã¢ããã®
ã¹ãããã³ãã³äžæŽèã䜿çšãããäœé420ã710
ïœã®ã¢ã«ã¢ããã«450ÎŒïœïŒKgã®ã¹ãããã³ãã³
ãæäžãããå¯Ÿç §çŸ€ã«ãããŠã¯ãåèšã®éã®ã¹
ãããã³ãã³ã®æäžã«ããäžæŽèçç¶ãçããã
ããŠ12ã20åé以å ã«åç©ãæ»ãã ãäžæŽèãæ
ããåç©ã«å¯ŸããŠè¢«æ€è¬å€ãéèå æäžãããã
ã®çµæã第ïŒè¡šã«ç€ºãããã®è©Šéšã«ããããã®çº
æã®å»è¬çµæç©åã³ããã«ã€ã³ã¢ãããéèå æ
äžããå ŽåãïŒåç©äžïŒåç©ã«ãããŠïŒã20éã«
ãããã¢ã«ã¢ããã®ã¹ãããã³ãã³èªå°äžæŽèã
äžæçã«é®æãããä»æ¹ããªãã«ã€ã³åã³ãããž
ã³ãæäžããå ŽåãããããïŒåç©äžïŒåç©åã³
ïŒåç©äžïŒåç©ã«ãããŠããã0.5ãïŒåéã«ã
ããçç¶ãæ¹åãããããšããECGã®ããŒã¿ã
ã瀺ãããã
ãè¡šã
åèè¡å§ãåŒåžãåã³ãã«ãšããããªã³ãããª
ãšããããªã³ããããšããããªã³ãã¢ã»ãã«ã³ãª
ã³åã³ãã¹ã¿ãã³ã®è¡æ¶²åæ å¹æã«é¢ããã¯ãã©
ããŒãŒã§éº»é ããäœé2.8ã4.0Kgã®ãã³ãçšããŠ
ãã®çºæã®è¬å€ãè©Šéšãããåç©ã®åèè¡å§ãåŒ
åžåã³ECGããã«ã³ã»ããªã»ã·ã¹ãã ã¹ç€Ÿè£œã
ã€ãžãªã°ã©ãã«èšé²ããã æäžé0.5ã2.0mgïŒKgã®éèå æäžã«ãã€ãŠ
ã¯ãéèè¡å§ãèææ°åã³åŒåžã«ãããªãæ¬è³ªç
å€åãçããªãããšãèŠåºããããè¬å€ã®äžèšã®
æäžéã«ãããŠã¯ãçç掻æ§ã¢ãã³é¡ã«å¯Ÿããå¿
çã¬ãã«ã®å€åãçããªãã€ããããã«é«ãè¬å€
æäžéïŒ15ã25mgïŒKgïŒã«ãããŠã¯ãéèè¡å§ã
çæéïŒã20mmHgäœäžããã®ã芳å¯ããã幟ã€
ãã®å Žåã«ã¯ãããã«é·æéïŒïŒã12åéïŒã«ã
ãããåèè¡å§ã¯æåã®å€ã«æ¯ã¹ãŠïŒã10mmHg
ã®äžæã«å€ãã€ããåæã«ããã¹ã¿ãã³ïŒïŒã10
ïŒ ïŒã«å¯Ÿããå¿çã®å¢å åã³ããªãšããããªã³
ïŒïŒã10ïŒ ïŒåã³ã¢ã»ãã«ã³ãªã³ïŒ10ã15ïŒ ïŒã®
æäžã«å¯Ÿããå¿çã®å€åã芳å¯ããããããã«è¬
å€ã®æäžéãå¢å ããŠãè¡å§ãåã³çç掻æ§ã¢ã
ã³é¡æäžã«å¯Ÿããå¿çã®å€åã¯çããªãã€ãã åããã®çºæã®å»è¬çµæç©åã³ã«ã«ãã¯ãã¡ã³
ã®å 埪ç°ãžã®åœ±é¿ã«ã€ããŠã®æ¯èŒè©Šéšãè¡ã€ãã
ãã®çºæã®å»è¬çµæç©ãšããŠã掻æ§æåãšããŠïŒ
âïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠã ïŒã
ãããªããŒãã0.9ïŒ å¡©åã«ã«ã·ãŠã 溶液ã溶解
ãããã20ïŒ æ³šå°æ¶²ã䜿çšããã äœé2.9ã4.1Kgã®éº»é ãããããã³ãçšããæ¥
æ§è©Šéšã«ãããŠã人工åŒåžæ¡äžã§ãç·é åèã«ã
ããåèè¡å§ãå³å¿æ¿ã«ãããäžå¿éèè¡å§ãäž
è¡å€§åèåŒã«ãããè¡æ¶²æµã®å®¹ç©é床åã³å è¡æµ
ã®å®¹ç©é床ãèšé²ãããåæã«ãå éèè¡äžã®é ž
åãã¢ã°ããã³ã®å«éãèšé²ããããã®çºæã®å»
è¬çµæç©ã®å¹æåã³ã«ã«ãã¯ãã¡ã³ã®å¹æã®æ¯èŒ
ããŒã¿ã第ïŒè¡šã«ç€ºãã è¡šãããããéãããã®çºæã®å»è¬çµæç©åã³
ãããšåäžæäžéã®ã«ã«ãã¯ãã¡ã³ã¯ãé·æéã«
ããããåèè¡å§ã«å€§ããªåœ±é¿ãäžããªãã§å è¡
液æµã®å®¹ç©é床ãå¢å ãããããäž¡è¬å€ãšãå¿è
è¡æ¶²æ¶åºéãå€åããããåã¯ãããã«å¢å ãã
ãããããã«ããã®çºæã®è¬å€ã¯ãã«ã«ãã¯ãã¡
ã³ãšåæ§ãå ç¶éèæŽã®éèè¡ã®é žçŽ 飜å床ãå¢
å ããããããä»æ¹ããã®çºæã®è¬å€ã®æ¯æ§ã¯ã
ã«ã«ãã¯ãã¡ã³ã®ããã«æ¯ã¹ãŠ12åå°ãªãããã®
ããããã®çºæã®æ°èŠå»è¬çµæç©ã®æ²»çææ°ã¯çŽ
ïŒåé«ãïŒ314察130ïŒã ããã«ããã®çºæã®è¬å€ã®ã¢ã¬ã«ã®ãŒçºçŸæ§ã«
ã€ããŠè©Šéšããããã®è©Šéšã«ããããã®è¬å€ã¯ã
éèå ã«æäžãããå Žåã«è¡ç®¡å£ãåºæ¿ããªãã®
ã¿ãªãããäžååã¯é·æéïŒ30æ¥ãŸã§ïŒã«ããã€
ãŠéèå æäžåã³è ¹è å æäžãããå Žåã§ãã¢ã¬
ã«ã®ãŒå¿çãçããããªãããšã瀺ãããã ãã¯ã€ãã©ããã䜿çšããè©Šéšã«ãããŠã
10000mgïŒKg以äžã®è¬å€ã¯åŠå©Šäžã®ãããªãææ
ã«çµå£æäžããŠããèæ¯äœçšåã¯èåå¯åœ¢çºçäœ
çšã¯èŠãããªãã€ããïŒâïŒïŒïŒïŒïŒïŒâããªã¡
ãã«ããã©ãžããŠã ïŒããããªããŒãäºæ°Žåç©ã
åºç€ã«ããè¬å€ã®ãããšåã³ãµã«ã¢ãã©èã«å¯Ÿã
ãå€ç°æºæ§è©Šéšã«ãããŠããã®çºæã®è¬å€ã¯å€ç°
æºæ§ãæããªãã€ãã ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠ
ã ïŒããããªããŒãäºæ°Žåç©ãåºç€ã«ããå»è¬çµ
æç©ã¯ãïŒïŒâã®æž©åºŠã«ãããïŒå¹Žé以äžã®è²¯èµ
ã«ãããŠå®å®ã§ãã€ãã
ãšããããªã³ããããšããããªã³ãã¢ã»ãã«ã³ãª
ã³åã³ãã¹ã¿ãã³ã®è¡æ¶²åæ å¹æã«é¢ããã¯ãã©
ããŒãŒã§éº»é ããäœé2.8ã4.0Kgã®ãã³ãçšããŠ
ãã®çºæã®è¬å€ãè©Šéšãããåç©ã®åèè¡å§ãåŒ
åžåã³ECGããã«ã³ã»ããªã»ã·ã¹ãã ã¹ç€Ÿè£œã
ã€ãžãªã°ã©ãã«èšé²ããã æäžé0.5ã2.0mgïŒKgã®éèå æäžã«ãã€ãŠ
ã¯ãéèè¡å§ãèææ°åã³åŒåžã«ãããªãæ¬è³ªç
å€åãçããªãããšãèŠåºããããè¬å€ã®äžèšã®
æäžéã«ãããŠã¯ãçç掻æ§ã¢ãã³é¡ã«å¯Ÿããå¿
çã¬ãã«ã®å€åãçããªãã€ããããã«é«ãè¬å€
æäžéïŒ15ã25mgïŒKgïŒã«ãããŠã¯ãéèè¡å§ã
çæéïŒã20mmHgäœäžããã®ã芳å¯ããã幟ã€
ãã®å Žåã«ã¯ãããã«é·æéïŒïŒã12åéïŒã«ã
ãããåèè¡å§ã¯æåã®å€ã«æ¯ã¹ãŠïŒã10mmHg
ã®äžæã«å€ãã€ããåæã«ããã¹ã¿ãã³ïŒïŒã10
ïŒ ïŒã«å¯Ÿããå¿çã®å¢å åã³ããªãšããããªã³
ïŒïŒã10ïŒ ïŒåã³ã¢ã»ãã«ã³ãªã³ïŒ10ã15ïŒ ïŒã®
æäžã«å¯Ÿããå¿çã®å€åã芳å¯ããããããã«è¬
å€ã®æäžéãå¢å ããŠãè¡å§ãåã³çç掻æ§ã¢ã
ã³é¡æäžã«å¯Ÿããå¿çã®å€åã¯çããªãã€ãã åããã®çºæã®å»è¬çµæç©åã³ã«ã«ãã¯ãã¡ã³
ã®å 埪ç°ãžã®åœ±é¿ã«ã€ããŠã®æ¯èŒè©Šéšãè¡ã€ãã
ãã®çºæã®å»è¬çµæç©ãšããŠã掻æ§æåãšããŠïŒ
âïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠã ïŒã
ãããªããŒãã0.9ïŒ å¡©åã«ã«ã·ãŠã 溶液ã溶解
ãããã20ïŒ æ³šå°æ¶²ã䜿çšããã äœé2.9ã4.1Kgã®éº»é ãããããã³ãçšããæ¥
æ§è©Šéšã«ãããŠã人工åŒåžæ¡äžã§ãç·é åèã«ã
ããåèè¡å§ãå³å¿æ¿ã«ãããäžå¿éèè¡å§ãäž
è¡å€§åèåŒã«ãããè¡æ¶²æµã®å®¹ç©é床åã³å è¡æµ
ã®å®¹ç©é床ãèšé²ãããåæã«ãå éèè¡äžã®é ž
åãã¢ã°ããã³ã®å«éãèšé²ããããã®çºæã®å»
è¬çµæç©ã®å¹æåã³ã«ã«ãã¯ãã¡ã³ã®å¹æã®æ¯èŒ
ããŒã¿ã第ïŒè¡šã«ç€ºãã è¡šãããããéãããã®çºæã®å»è¬çµæç©åã³
ãããšåäžæäžéã®ã«ã«ãã¯ãã¡ã³ã¯ãé·æéã«
ããããåèè¡å§ã«å€§ããªåœ±é¿ãäžããªãã§å è¡
液æµã®å®¹ç©é床ãå¢å ãããããäž¡è¬å€ãšãå¿è
è¡æ¶²æ¶åºéãå€åããããåã¯ãããã«å¢å ãã
ãããããã«ããã®çºæã®è¬å€ã¯ãã«ã«ãã¯ãã¡
ã³ãšåæ§ãå ç¶éèæŽã®éèè¡ã®é žçŽ 飜å床ãå¢
å ããããããä»æ¹ããã®çºæã®è¬å€ã®æ¯æ§ã¯ã
ã«ã«ãã¯ãã¡ã³ã®ããã«æ¯ã¹ãŠ12åå°ãªãããã®
ããããã®çºæã®æ°èŠå»è¬çµæç©ã®æ²»çææ°ã¯çŽ
ïŒåé«ãïŒ314察130ïŒã ããã«ããã®çºæã®è¬å€ã®ã¢ã¬ã«ã®ãŒçºçŸæ§ã«
ã€ããŠè©Šéšããããã®è©Šéšã«ããããã®è¬å€ã¯ã
éèå ã«æäžãããå Žåã«è¡ç®¡å£ãåºæ¿ããªãã®
ã¿ãªãããäžååã¯é·æéïŒ30æ¥ãŸã§ïŒã«ããã€
ãŠéèå æäžåã³è ¹è å æäžãããå Žåã§ãã¢ã¬
ã«ã®ãŒå¿çãçããããªãããšã瀺ãããã ãã¯ã€ãã©ããã䜿çšããè©Šéšã«ãããŠã
10000mgïŒKg以äžã®è¬å€ã¯åŠå©Šäžã®ãããªãææ
ã«çµå£æäžããŠããèæ¯äœçšåã¯èåå¯åœ¢çºçäœ
çšã¯èŠãããªãã€ããïŒâïŒïŒïŒïŒïŒïŒâããªã¡
ãã«ããã©ãžããŠã ïŒããããªããŒãäºæ°Žåç©ã
åºç€ã«ããè¬å€ã®ãããšåã³ãµã«ã¢ãã©èã«å¯Ÿã
ãå€ç°æºæ§è©Šéšã«ãããŠããã®çºæã®è¬å€ã¯å€ç°
æºæ§ãæããªãã€ãã ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠ
ã ïŒããããªããŒãäºæ°Žåç©ãåºç€ã«ããå»è¬çµ
æç©ã¯ãïŒïŒâã®æž©åºŠã«ãããïŒå¹Žé以äžã®è²¯èµ
ã«ãããŠå®å®ã§ãã€ãã
ãè¡šã
çš®ã
ã®ç
å ã«ããäžæŽèãèè¡æ§å¿çŸæ£ãçå¿
çãã¢ãããŒã æ§åè硬åçã®ããšãåçš®ã®å¿è
âè¡ç®¡ç³»çŸæ£ãæããæ£è 65人以äžãçšããŠè¬å€
ã®è©Šéšãè¡ã€ãã è¬å€æäžã®ããã®ææšã¯çžåœå°ãªãã€ãããèš
åºè©ŠéšãéããŠãäž»ãšããŠèè¡æ§å¿çŸæ£æ£è
ïŒIHDïŒã«æäžããã25æ³ã50æ³ã®ç·å¥³20人ã«ã€
ããŠã®è¬å€ã®å¹æã®è§£æçµæãåŸã§ç€ºãã ãã¹ãŠã®æ£è ã¯å žåççå¿çã«çœ¹æ£ããŠããã
ïŒäººã®æ£è ã«ã¯ãã³ãããã°ã©ãã€ãŒã«ããå ç¶
èã«é¡èãªç å€ãèªãããããããŠãïŒäººã®æ£è
ã«ã¯ECGäžã®ç çç波ã䌎ãªã倧ç å·£å¿çæ¢
å¡ã®æ¢åŸçãèªããããããã¹ãŠã®æ£è ã«ã掻æ§
æåã®æäžéãäœéïŒKgåœãã20ã40mgãšãªãã
ãã«è¬å€ãçµå£æäžãããããããã®æ£è ã«ãæŒ
éãé£äºãšå ±ã«ïŒé±éã«ããã€ãŠæäžãããå šæ²»
çæéãéããŠã®æäžéã¯å¹³å48ã96ïœã§ãã€
ãã 次ã®è¡æ¶²åæ ãã©ã¡ãŒã¿ããªãã¡ãå¿æ¶æ°
ïŒRHBïŒãå¿é»å³ïŒECGïŒãã¡ã«ãã«ã«ãžãªã°ã©ã
ïŒMechanocardiographïŒ063ããµãã¹ããŒå
ïŒSavitskyâ²s modelïŒäžã«èšé²ãããæ²ç·ã«ãã
æ±ãããã¹ãŠã®çš®é¡ã®åèè¡å§ãã¬ã ãµãŒâã©ã³
ãïŒWremserâRankeïŒæ³ã«åŸã€ãŠæ±ããæ¶åº
éããã«ã¹æ³¢äŒæ¬é床ããã³ãŽã°ã©ã
ïŒMingogradhïŒïŒâ34è£ çœ®ã«ããå·Šå¿å®€åçž®ã®äœ
çžåæåã³æ¯å¹ âæéãã©ã¡ãŒã¿ãæ¶åºå®¹ç©é床
ïŒVREïŒãå§åå¢å é床ïŒSPGïŒãå¿èåŒç·©é床
ïŒRHRïŒãã枬å®ããã è©ŠéšæéäžãIHDã«çœ¹æ£ããæ£è ã¯çåãç¶ã
ããå¿ èŠã«å¿ããŠãããã°ãªã»ãªã³ãæäžããã®
ãé€ãä»ã®äžåã®è¬å€æäžã¯è¡ããªãã€ãã è¬å€ã®æäžãéå§ããŠç¬¬äžé±ã«ãããŠããæ£è
ã®å¥åº·ç¶æ ã«çžåœããæ¹åãèŠããããããªã
ã¡ãèžéªšåŸéšççºçé »åºŠãäœäžããåŒåžå°é£ãé¡
èã§ãªããªããïŒæ¥åœããã®ãããã°ãªã»ãªã³é
ã®æäžåæ°ãæ¥éã«æžå°ããäœæ¥å®¹éãå¢å ãã
足ã®è±åãæ¶å€±ããå¿èã®éæ¬ ãå°ãªããªã€ãã å¿é»å³ã«ããè©Šéšã«ãã€ãŠãå¿æ¶æ°ã®ããããª
æžå°ãå¿æ¿æ§åã³å¿å®€æ§æå€åçž®ã®æ¶å€±ã波ã®
åçŸåã³ãã®æ£æ¯å¹ ã®å¢å ãèªãããããåèè¡
å§ã«ã€ããŠã®è©Šéšã«ãããŠãããããçš®é¡ã®
APãç¹ã«è¡æ¶²æµåã®ååŠçãšãã«ã®ãŒã®å¢å ã
瀺ãè¡æ¶²æµåè¡æ䟡ã®å¢å ã芳ç¥ããããåèè¡
å§ã®äžæã¯äž»ãšããŠæ¶åºéã®å¢å ã䌎ããäžæ¹åŒŸ
æ§ååã³çèåè¡ç®¡ã®ç·åŒµã¯å®è³ªäžå€åãããã
ã®ããšã¯èæ³¢ã®äŒæ¬é床å€ã«ãã瀺ãããã æ²»çäžã«ãããå·Šå¿å®€ã®äœçžè§£æã«ãããŠãé
çž®æïŒïŒŽïŒã¯æããã«é·ããªããæŸåºçžïŒïŒ¥ïŒã¯
çãããªããç·åŒµæïŒPTïŒã¯äž»ãšããŠçå°ºæ§å
çž®ïŒICïŒæã®ççž®ã«ããççž®ãããã å¿çåçž®ã«ãããåçž®æåã³æ¡åŒµæããããã«
ã€ããŠå¿çå±€ã®åçž®æ§ãè©äŸ¡ããããã«ãæ¯å¹ â
æéç¹æ§ãããªãã¡ãå¿èæŸåºé床ïŒRHEïŒãè¡
å§äžæé床ïŒRPRïŒåã³å¿èåŒç·©é床ïŒRHRïŒ
ã䜿çšããã å¿èæŸåºé床ïŒRHEïŒã¯åŒBV6ïŒïŒ¥ã«ããç®
å®ãããããã§ãBVã¯æ¶åºéïŒmlïŒã§ããã
ã¯æŸåºçžæéïŒç§ïŒã§ããã RHEå€ã¯ãåçž®æã«ãããå¿çå±€ã®åçž®æ§ã
ç¹è²ããããã®çºæã®è¬å€ã«ããæ²»çæéäžã®ã
ã®å€ã®äžæã¯ãå¿çå±€ã®å€åæ§ã®æ¹åãæå³ã
ãã è¡å§äžæé床ã¯åŒRPRïŒïŒDPâïŒïŒïŒICã«ãã
ç®åºããããããã§DPã¯æ¡åŒµæè¡å§ïŒmmHgïŒã
ïŒã¯å€§åèäžã®æçµæ¡åŒµæè¡å§ã®éåžžå€ã§ããã
ICã¯çå°ºæ§åçž®ã§ãããRPRã¯åŒéæ¢æã«ãã
ãå¿çå±€ã®åçž®æ§åã³å€§åèåŒã®éæŸã®éã®å€§å
èäžã®è¡å§äŸ¡ãæ¥éã«äžæããããå¿çå±€ã®èœå
ãç¹è²ãããã å¿èåŒç·©é床ïŒRHRïŒã¯æ¡åŒµæã«ãããå¿ç
å±€ã®æŽ»æ§ãç¹è²ãããåŒRHRïŒïŒSPâïŒïŒïŒïŒ€ã«
ããç®åºããããããã§ãSPã¯äžè åèã«ãã
ãåçž®æè¡å§ïŒmmHgïŒã§ãããïŒã¯å€§åèã«ã
ããæçµæ¡åŒµæè¡å§ã®éåžžå€ã§ãããã¯æ¡åŒµæ
ã®æç¶æéïŒç§ïŒã§ãããè©Šéšã®çµæã¯ç¬¬ïŒè¡šã«
瀺ãã
çãã¢ãããŒã æ§åè硬åçã®ããšãåçš®ã®å¿è
âè¡ç®¡ç³»çŸæ£ãæããæ£è 65人以äžãçšããŠè¬å€
ã®è©Šéšãè¡ã€ãã è¬å€æäžã®ããã®ææšã¯çžåœå°ãªãã€ãããèš
åºè©ŠéšãéããŠãäž»ãšããŠèè¡æ§å¿çŸæ£æ£è
ïŒIHDïŒã«æäžããã25æ³ã50æ³ã®ç·å¥³20人ã«ã€
ããŠã®è¬å€ã®å¹æã®è§£æçµæãåŸã§ç€ºãã ãã¹ãŠã®æ£è ã¯å žåççå¿çã«çœ¹æ£ããŠããã
ïŒäººã®æ£è ã«ã¯ãã³ãããã°ã©ãã€ãŒã«ããå ç¶
èã«é¡èãªç å€ãèªãããããããŠãïŒäººã®æ£è
ã«ã¯ECGäžã®ç çç波ã䌎ãªã倧ç å·£å¿çæ¢
å¡ã®æ¢åŸçãèªããããããã¹ãŠã®æ£è ã«ã掻æ§
æåã®æäžéãäœéïŒKgåœãã20ã40mgãšãªãã
ãã«è¬å€ãçµå£æäžãããããããã®æ£è ã«ãæŒ
éãé£äºãšå ±ã«ïŒé±éã«ããã€ãŠæäžãããå šæ²»
çæéãéããŠã®æäžéã¯å¹³å48ã96ïœã§ãã€
ãã 次ã®è¡æ¶²åæ ãã©ã¡ãŒã¿ããªãã¡ãå¿æ¶æ°
ïŒRHBïŒãå¿é»å³ïŒECGïŒãã¡ã«ãã«ã«ãžãªã°ã©ã
ïŒMechanocardiographïŒ063ããµãã¹ããŒå
ïŒSavitskyâ²s modelïŒäžã«èšé²ãããæ²ç·ã«ãã
æ±ãããã¹ãŠã®çš®é¡ã®åèè¡å§ãã¬ã ãµãŒâã©ã³
ãïŒWremserâRankeïŒæ³ã«åŸã€ãŠæ±ããæ¶åº
éããã«ã¹æ³¢äŒæ¬é床ããã³ãŽã°ã©ã
ïŒMingogradhïŒïŒâ34è£ çœ®ã«ããå·Šå¿å®€åçž®ã®äœ
çžåæåã³æ¯å¹ âæéãã©ã¡ãŒã¿ãæ¶åºå®¹ç©é床
ïŒVREïŒãå§åå¢å é床ïŒSPGïŒãå¿èåŒç·©é床
ïŒRHRïŒãã枬å®ããã è©ŠéšæéäžãIHDã«çœ¹æ£ããæ£è ã¯çåãç¶ã
ããå¿ èŠã«å¿ããŠãããã°ãªã»ãªã³ãæäžããã®
ãé€ãä»ã®äžåã®è¬å€æäžã¯è¡ããªãã€ãã è¬å€ã®æäžãéå§ããŠç¬¬äžé±ã«ãããŠããæ£è
ã®å¥åº·ç¶æ ã«çžåœããæ¹åãèŠããããããªã
ã¡ãèžéªšåŸéšççºçé »åºŠãäœäžããåŒåžå°é£ãé¡
èã§ãªããªããïŒæ¥åœããã®ãããã°ãªã»ãªã³é
ã®æäžåæ°ãæ¥éã«æžå°ããäœæ¥å®¹éãå¢å ãã
足ã®è±åãæ¶å€±ããå¿èã®éæ¬ ãå°ãªããªã€ãã å¿é»å³ã«ããè©Šéšã«ãã€ãŠãå¿æ¶æ°ã®ããããª
æžå°ãå¿æ¿æ§åã³å¿å®€æ§æå€åçž®ã®æ¶å€±ã波ã®
åçŸåã³ãã®æ£æ¯å¹ ã®å¢å ãèªãããããåèè¡
å§ã«ã€ããŠã®è©Šéšã«ãããŠãããããçš®é¡ã®
APãç¹ã«è¡æ¶²æµåã®ååŠçãšãã«ã®ãŒã®å¢å ã
瀺ãè¡æ¶²æµåè¡æ䟡ã®å¢å ã芳ç¥ããããåèè¡
å§ã®äžæã¯äž»ãšããŠæ¶åºéã®å¢å ã䌎ããäžæ¹åŒŸ
æ§ååã³çèåè¡ç®¡ã®ç·åŒµã¯å®è³ªäžå€åãããã
ã®ããšã¯èæ³¢ã®äŒæ¬é床å€ã«ãã瀺ãããã æ²»çäžã«ãããå·Šå¿å®€ã®äœçžè§£æã«ãããŠãé
çž®æïŒïŒŽïŒã¯æããã«é·ããªããæŸåºçžïŒïŒ¥ïŒã¯
çãããªããç·åŒµæïŒPTïŒã¯äž»ãšããŠçå°ºæ§å
çž®ïŒICïŒæã®ççž®ã«ããççž®ãããã å¿çåçž®ã«ãããåçž®æåã³æ¡åŒµæããããã«
ã€ããŠå¿çå±€ã®åçž®æ§ãè©äŸ¡ããããã«ãæ¯å¹ â
æéç¹æ§ãããªãã¡ãå¿èæŸåºé床ïŒRHEïŒãè¡
å§äžæé床ïŒRPRïŒåã³å¿èåŒç·©é床ïŒRHRïŒ
ã䜿çšããã å¿èæŸåºé床ïŒRHEïŒã¯åŒBV6ïŒïŒ¥ã«ããç®
å®ãããããã§ãBVã¯æ¶åºéïŒmlïŒã§ããã
ã¯æŸåºçžæéïŒç§ïŒã§ããã RHEå€ã¯ãåçž®æã«ãããå¿çå±€ã®åçž®æ§ã
ç¹è²ããããã®çºæã®è¬å€ã«ããæ²»çæéäžã®ã
ã®å€ã®äžæã¯ãå¿çå±€ã®å€åæ§ã®æ¹åãæå³ã
ãã è¡å§äžæé床ã¯åŒRPRïŒïŒDPâïŒïŒïŒICã«ãã
ç®åºããããããã§DPã¯æ¡åŒµæè¡å§ïŒmmHgïŒã
ïŒã¯å€§åèäžã®æçµæ¡åŒµæè¡å§ã®éåžžå€ã§ããã
ICã¯çå°ºæ§åçž®ã§ãããRPRã¯åŒéæ¢æã«ãã
ãå¿çå±€ã®åçž®æ§åã³å€§åèåŒã®éæŸã®éã®å€§å
èäžã®è¡å§äŸ¡ãæ¥éã«äžæããããå¿çå±€ã®èœå
ãç¹è²ãããã å¿èåŒç·©é床ïŒRHRïŒã¯æ¡åŒµæã«ãããå¿ç
å±€ã®æŽ»æ§ãç¹è²ãããåŒRHRïŒïŒSPâïŒïŒïŒïŒ€ã«
ããç®åºããããããã§ãSPã¯äžè åèã«ãã
ãåçž®æè¡å§ïŒmmHgïŒã§ãããïŒã¯å€§åèã«ã
ããæçµæ¡åŒµæè¡å§ã®éåžžå€ã§ãããã¯æ¡åŒµæ
ã®æç¶æéïŒç§ïŒã§ãããè©Šéšã®çµæã¯ç¬¬ïŒè¡šã«
瀺ãã
ãè¡šã
ãè¡šã
ãã®çºæã®è¬å€ã®æã¢ã³ã®ãäœçšåã³æäžæŽè
äœçšãã泚å°çšè£œå€ã䜿çšããŠæŽ»æ§æåã0.2ã
0.4ïœãšãªãããã«éèå æäžããããšã«ããè©
䟡ãããçå¿ççºäœïŒçäŸäžïŒçäŸã«ãããŠãå¥
éç¡é žååç©ãé®çè¬åã³éº»é è¬ãæäžããããš
ãªãããã®çºæã®è¬å€ãæäžããããšã«ããèžéªš
åŸéšçãæ¥éã«ïŒæ¬¡çã«é®æããããšãã§ããã
ããããªããããã®è¬å€ã®é®çäœçšã¯åžžã«å®å®ã¯
ãªããè¬å€ã®å埩æäžãå¿ èŠã§ãã€ãã æåŸåçž®æ§äžæŽèã®ïŒäººã®æ£è ã®çäŸã«ã€ã
ãŠãè¬å€ã®å¹æãè©Šéšãããè¬å€ïŒ40ïŒ æº¶æ¶²ïŒ
mlïŒãéèå æäžããããšã«ãããïŒã20åéäž
æŽèãé€å»ããããšãã§ããã 以äžã®ããšããïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«
ããã©ãžããŠã ïŒããããªããŒãã掻æ§æåãšã
ãå»è¬çµæç©ã¯ãæããã¯èè¡æ§çŸæ£ãæããæ£
è ã«ãããŠãå¿çå±€ã«å€åäœçšãåãŒããæå€å
çž®ãšåæ§èžéªšåŸéšçåã³äžæŽèãé€å»ããã åŸã€ãŠããã®çºæã®å»è¬çµæç©ã¯ãç¹å®ã®äœçš
ç¯å²ãæãããããªãã¡ããã®è¬å€ã¯ãå ç¶åè
ã«å¯Ÿããè¡ç®¡æ¡åŒµå€ãšããŠäœçšããå¿ç局代è¬ã®
æ¹åãå©é·ãããããŠãæããã«åè¶ãããäžã€
å®å®ãªç©æ¥µçå€åäœçšãæããã ãã®çºæã®å»è¬çµæç©ã¯ã泚å°æ¶²ãé å€ãã«ã
ã»ã«å€åã³ç²å€ãšããŠæäžããã®ã奜ãŸãããã
ã®è¬å€ã¯ãæ¥çšéäœéïŒKgåœã10ã60mgã®å²å
ã§ãé å€åã¯ã«ãã»ã«å€ã®åœ¢ã§é£äºãšå ±ã«æäž
ããåã¯10ã40ïŒ æ³šå°æ¶²ã®åã§æäžããããã®çº
æã®è¬å€ã¯äœæ¯æ§ç©è³ªã«å±ããïŒïŒèŠ§è¡šïŒ¢ãåã¯
ããããå³æ Œã§ãªãïŒã çµå£çšè£œå€ã¯ã宀枩ã«ãããŠïŒå¹Žéå®å®ã§ã
ãã也ç¥ããææã«è²¯èµããå¿ èŠãããã泚å°æ¶²
ã®æ¶²ã®è²¯èµã¯ïŒâ以äžã®æž©åºŠãšããïŒå¹Žéæªæºãš
ãã¹ãã§ããã ãã®çºæã®æŽ»æ§æåããªãã¡ïŒâïŒïŒïŒïŒïŒïŒ
âããªã¡ãã«ããã©ãžããŠã ïŒããããªããŒã
ã¯ãä»»æã®åžžæ³ã«ãã補é ããããšãã§ãããäŸ
ãã°ãã¡ãã«âïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ã
ãã©ãžããŠã ïŒããããªããŒãã¯ããªãã®æ°Žæº¶æ¶²
ããã€ãªã³äº€ææš¹èã¢ã³ããŒã©ã€ãIRAâ400
ïŒç»é²åæšïŒãå å¡«ããã«ã©ã ã«éãã溶å€ãé€
å»ãããããŠæ®æž£ããšã¿ããŒã«ããçµæ¶ããã
ããããããŠ140ïœïŒ85ïŒ ïŒã®ïŒâïŒïŒïŒïŒïŒïŒ
âããªã¡ãã«ããã©ãžããŠã ïŒããããªããŒãã
ç¡è²ã®çµæ¶ãšããŠåŸãããã®ååç©ã¯ãèç¹254
ã256âãRMRã¹ãã¯ãã«ïŒÏïŒppmïŒïŒ6.79ã·
ã¯ã°ã¬ãããïŒCH3ïŒ3N+ïŒ6.89ããªãã¬ããã
CH2ïŒ7.77ããªãã¬ãããCH2ïŒã§ããã å çŽ åæå€ïŒïŒ ïŒã¯ãïŒ39.56ïŒïŒšïŒ10.10ïŒ
ïŒ15.36ïŒã§ãã€ãŠåååŒã¯C6H14O2N2ã»2H2O
ã§ããããã®èšç®å€ïŒïŒ ïŒã¯ã ïŒ39.56ïŒïŒšïŒ9.89ïŒïŒ®ïŒ15.30ïŒã§ããã ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠ
ã ïŒããããªããŒãäºæ°Žåç©ã¯ããããã«åžæ¹¿æ§
ã®çœè²ç©è³ªã§ãããæ°Žãç±ã¢ã«ã³ãŒã«åã³ã¡ã¿ã
ãŒã«ã«ãã溶ããé極æ§æº¶å€ã«äžæº¶ã§ããã匱ã
ç¹æã®èãæããã宀枩ã«ãããŠå¯é容åšã«è²¯èµ
ããå ŽåãïŒå¹Žé以äžå®å®ã§ããã40âããé«æž©
ã«å ç±ããå Žåããã®ç©è³ªã¯çµæ¶æ°Žã倱ãããã
ãŠåŸã ã«å解ããã
äœçšãã泚å°çšè£œå€ã䜿çšããŠæŽ»æ§æåã0.2ã
0.4ïœãšãªãããã«éèå æäžããããšã«ããè©
䟡ãããçå¿ççºäœïŒçäŸäžïŒçäŸã«ãããŠãå¥
éç¡é žååç©ãé®çè¬åã³éº»é è¬ãæäžããããš
ãªãããã®çºæã®è¬å€ãæäžããããšã«ããèžéªš
åŸéšçãæ¥éã«ïŒæ¬¡çã«é®æããããšãã§ããã
ããããªããããã®è¬å€ã®é®çäœçšã¯åžžã«å®å®ã¯
ãªããè¬å€ã®å埩æäžãå¿ èŠã§ãã€ãã æåŸåçž®æ§äžæŽèã®ïŒäººã®æ£è ã®çäŸã«ã€ã
ãŠãè¬å€ã®å¹æãè©Šéšãããè¬å€ïŒ40ïŒ æº¶æ¶²ïŒ
mlïŒãéèå æäžããããšã«ãããïŒã20åéäž
æŽèãé€å»ããããšãã§ããã 以äžã®ããšããïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«
ããã©ãžããŠã ïŒããããªããŒãã掻æ§æåãšã
ãå»è¬çµæç©ã¯ãæããã¯èè¡æ§çŸæ£ãæããæ£
è ã«ãããŠãå¿çå±€ã«å€åäœçšãåãŒããæå€å
çž®ãšåæ§èžéªšåŸéšçåã³äžæŽèãé€å»ããã åŸã€ãŠããã®çºæã®å»è¬çµæç©ã¯ãç¹å®ã®äœçš
ç¯å²ãæãããããªãã¡ããã®è¬å€ã¯ãå ç¶åè
ã«å¯Ÿããè¡ç®¡æ¡åŒµå€ãšããŠäœçšããå¿ç局代è¬ã®
æ¹åãå©é·ãããããŠãæããã«åè¶ãããäžã€
å®å®ãªç©æ¥µçå€åäœçšãæããã ãã®çºæã®å»è¬çµæç©ã¯ã泚å°æ¶²ãé å€ãã«ã
ã»ã«å€åã³ç²å€ãšããŠæäžããã®ã奜ãŸãããã
ã®è¬å€ã¯ãæ¥çšéäœéïŒKgåœã10ã60mgã®å²å
ã§ãé å€åã¯ã«ãã»ã«å€ã®åœ¢ã§é£äºãšå ±ã«æäž
ããåã¯10ã40ïŒ æ³šå°æ¶²ã®åã§æäžããããã®çº
æã®è¬å€ã¯äœæ¯æ§ç©è³ªã«å±ããïŒïŒèŠ§è¡šïŒ¢ãåã¯
ããããå³æ Œã§ãªãïŒã çµå£çšè£œå€ã¯ã宀枩ã«ãããŠïŒå¹Žéå®å®ã§ã
ãã也ç¥ããææã«è²¯èµããå¿ èŠãããã泚å°æ¶²
ã®æ¶²ã®è²¯èµã¯ïŒâ以äžã®æž©åºŠãšããïŒå¹Žéæªæºãš
ãã¹ãã§ããã ãã®çºæã®æŽ»æ§æåããªãã¡ïŒâïŒïŒïŒïŒïŒïŒ
âããªã¡ãã«ããã©ãžããŠã ïŒããããªããŒã
ã¯ãä»»æã®åžžæ³ã«ãã補é ããããšãã§ãããäŸ
ãã°ãã¡ãã«âïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ã
ãã©ãžããŠã ïŒããããªããŒãã¯ããªãã®æ°Žæº¶æ¶²
ããã€ãªã³äº€ææš¹èã¢ã³ããŒã©ã€ãIRAâ400
ïŒç»é²åæšïŒãå å¡«ããã«ã©ã ã«éãã溶å€ãé€
å»ãããããŠæ®æž£ããšã¿ããŒã«ããçµæ¶ããã
ããããããŠ140ïœïŒ85ïŒ ïŒã®ïŒâïŒïŒïŒïŒïŒïŒ
âããªã¡ãã«ããã©ãžããŠã ïŒããããªããŒãã
ç¡è²ã®çµæ¶ãšããŠåŸãããã®ååç©ã¯ãèç¹254
ã256âãRMRã¹ãã¯ãã«ïŒÏïŒppmïŒïŒ6.79ã·
ã¯ã°ã¬ãããïŒCH3ïŒ3N+ïŒ6.89ããªãã¬ããã
CH2ïŒ7.77ããªãã¬ãããCH2ïŒã§ããã å çŽ åæå€ïŒïŒ ïŒã¯ãïŒ39.56ïŒïŒšïŒ10.10ïŒ
ïŒ15.36ïŒã§ãã€ãŠåååŒã¯C6H14O2N2ã»2H2O
ã§ããããã®èšç®å€ïŒïŒ ïŒã¯ã ïŒ39.56ïŒïŒšïŒ9.89ïŒïŒ®ïŒ15.30ïŒã§ããã ïŒâïŒïŒïŒïŒïŒïŒâããªã¡ãã«ããã©ãžããŠ
ã ïŒããããªããŒãäºæ°Žåç©ã¯ããããã«åžæ¹¿æ§
ã®çœè²ç©è³ªã§ãããæ°Žãç±ã¢ã«ã³ãŒã«åã³ã¡ã¿ã
ãŒã«ã«ãã溶ããé極æ§æº¶å€ã«äžæº¶ã§ããã匱ã
ç¹æã®èãæããã宀枩ã«ãããŠå¯é容åšã«è²¯èµ
ããå ŽåãïŒå¹Žé以äžå®å®ã§ããã40âããé«æž©
ã«å ç±ããå Žåããã®ç©è³ªã¯çµæ¶æ°Žã倱ãããã
ãŠåŸã ã«å解ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ æ¬¡ã®æ§é åŒã ïŒCH3ïŒ3N+NHCH2CH2COO-ã»2H2O ã§ç€ºããã掻æ§æåïŒâïŒïŒïŒïŒïŒïŒâããªã¡ã
ã«ããã©ãžããŠã ïŒããããªããŒãäºæ°Žåç©åã³
å»è¬ãšããŠèš±å®¹ãããåžéå€ãå«ãã§æãæäžæŽ
èäœçšåã³æã¢ã³ã®ãäœçšãæããå»è¬çµæç©ã ïŒ æŽ»æ§æåãïŒééïŒ ã40ééïŒ ãå«ã泚å°è¬
ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®å»è¬çµæç©ã ïŒ å»è¬ãšããŠèš±å®¹ãããåžéå€ãšããŠæº¶åªããª
ãã¡èžçæ°Žåã¯ç匵溶液ã䜿çšãã泚å°è¬ã§ãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®å»è¬çµæç©ã ïŒ æŽ»æ§æåãé å€åã¯ã«ãã»ã«åœã0.1ã0.5ïœ
å«ãé å€åã¯ã«ãã»ã«å€ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé èšèŒã®å»è¬çµæç©ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU3374766 | 1981-09-17 | ||
| SU3374766 | 1981-09-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5874606A JPS5874606A (ja) | 1983-05-06 |
| JPS6129927B2 true JPS6129927B2 (ja) | 1986-07-10 |
Family
ID=20989831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57161129A Granted JPS5874606A (ja) | 1981-09-17 | 1982-09-17 | å¿èâè¡ç®¡ç³»çŸæ£æ²»ççšçµæç© |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4451485A (ja) |
| JP (1) | JPS5874606A (ja) |
| DE (1) | DE3234537C2 (ja) |
| FR (1) | FR2512671A1 (ja) |
| GB (1) | GB2105992B (ja) |
| IT (1) | IT1210935B (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1224490A (en) * | 1983-05-18 | 1987-07-21 | Gunar A. Bremanis | 3(2,2,2-trisubstituted hydrazinium) propionates |
| SU1680693A1 (ru) * | 1987-03-25 | 1991-09-30 | ÐÐœÑÑОÑÑÑ ÐÑгаМОÑеÑкПгП СОМÑеза ÐÐœ ÐаÑвÑÑÑ | ÐÑОл-3-(2,2-ЎОЌеÑОл-2-ÑÑОлгОЎÑазОМОй)пÑÐŸÐ¿ÐžÐŸÐœÐ°Ñ ÐžÐŸÐŽÐžÑÑÑй, пÑП вл ÑÑОй аМÑОаÑОÑЌОÑеÑкÑÑ Ð°ÐºÑОвМПÑÑÑ |
| LV11727B (en) * | 1995-08-21 | 1997-08-20 | Kalvins Ivars | Pharmaceutical composition |
| LV11728B (en) * | 1995-08-21 | 1997-08-20 | Kalvins Ivars | Pharmaceutical composition |
| WO2009074498A1 (en) * | 2007-12-12 | 2009-06-18 | Grindeks | Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate |
| LV14345B (lv) | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai |
| US8940793B2 (en) | 2011-04-27 | 2015-01-27 | Jsc Grindeks | 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease |
| CA2832693C (en) | 2011-04-27 | 2018-10-02 | Grindeks, A Joint Stock Company | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
| RU2467748C1 (ru) * | 2011-08-08 | 2012-11-27 | ЀеЎеÑалÑМПе гПÑÑЎаÑÑÑвеММПе авÑПМПЌМПе ПбÑазПваÑелÑМПе ÑÑÑежЎеМОе вÑÑÑегП пÑПÑеÑÑОПМалÑМПгП ПбÑÐ°Ð·ÐŸÐ²Ð°ÐœÐžÑ "ÐелгПÑПЎÑкОй гПÑÑЎаÑÑÑвеММÑй МаÑОПМалÑÐœÑй ОÑÑлеЎПваÑелÑÑкОй ÑМОвеÑÑОÑеÑ" | ÐÑПОзвПЎМПе 3-(2,2,2-ÑÑОЌеÑОлгОЎÑазОМОй)пÑПпОПМаÑа - глОÑÐžÐœÐ°Ñ 3-(2,2,2-ÑÑОЌеÑОлгОЎÑазОМОй)пÑÐŸÐ¿ÐžÐŸÐœÐ°Ñ ÐºÐ°Ð»ÐžÑ, ПблаЎаÑÑее ÑМЎПÑелОПпÑПÑекÑПÑМПй акÑОвМПÑÑÑÑ |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU997646A1 (ru) * | 1978-11-27 | 1983-02-23 | ÐÑЎеМа ТÑÑЎПвПгП ÐÑаÑМПгП ÐМаЌеМО ÐÐœÑÑОÑÑÑ ÐÑгаМОÑеÑкПгП СОМÑеза ÐÐœ ÐаÑвÑÑÑ | ÐПÑЌПва ЎПбавка |
| BE880831A (fr) * | 1979-12-21 | 1980-06-23 | Inst Organicheskogo Sinteza Ak | Le (trimethyl -2,2,2 hydrazinium9-3 propionate, procede de preparation et application |
-
1982
- 1982-09-16 IT IT8223309A patent/IT1210935B/it active
- 1982-09-17 US US06/419,454 patent/US4451485A/en not_active Expired - Lifetime
- 1982-09-17 JP JP57161129A patent/JPS5874606A/ja active Granted
- 1982-09-17 DE DE3234537A patent/DE3234537C2/de not_active Expired
- 1982-09-17 FR FR8215731A patent/FR2512671A1/fr active Granted
- 1982-09-17 GB GB08226494A patent/GB2105992B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2512671A1 (fr) | 1983-03-18 |
| FR2512671B1 (ja) | 1984-06-15 |
| JPS5874606A (ja) | 1983-05-06 |
| GB2105992A (en) | 1983-04-07 |
| GB2105992B (en) | 1985-05-30 |
| DE3234537A1 (de) | 1983-04-07 |
| IT1210935B (it) | 1989-09-29 |
| US4451485A (en) | 1984-05-29 |
| IT8223309A0 (it) | 1982-09-16 |
| DE3234537C2 (de) | 1986-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SOUTHWORTH et al. | Ventricular fibrillation precipitated by cardiac catheterization: Complete recovery of the patient after forty-five minutes | |
| AU779238B2 (en) | Use of pyridoxine compounds for treatment of carsiovascular and related pathologies | |
| Glancy et al. | Effect of swallowed isosorbide dinitrate on blood pressure, heart rate and exercise capacity in patients with coronary artery disease | |
| KR20110026422A (ko) | ì구ì ì¬ë°© ìžëì ìë°©ì ìí ëë¡ë€ë€ë¡ | |
| JP2011518785A (ja) | å¿è¡ç®¡å ¥é¢ãŸãã¯æ»äº¡ã®äºé²ã«çšããè¬å€ã調補ããããã®ãããããã³ã®äœ¿çš | |
| US4210670A (en) | Antithrombotic agents | |
| JPS6129927B2 (ja) | ||
| US4713370A (en) | Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats | |
| JPH01113317A (ja) | æäžæŽèå€ | |
| JPH0341448B2 (ja) | ||
| KR0136787B1 (ko) | ì¬ì¥ì§í ì¹ë£ì ì°ìŽë íë¡ííë Œê³Œ íŽëëì ì§ìì± ì¡°ì±ë¬Œ | |
| US3932652A (en) | Antidepressant compositions | |
| JPS60323B2 (ja) | ãã€è¡æ§å¿äžå šæ²»ççšçµæç© | |
| CA1185528A (en) | Pharmaceutical composition for the treatment of cardio-vascular diseases | |
| Svedmyr et al. | Effects of sotalol and propranolol administered orally in man | |
| Gupta et al. | Transient atrioventricular standstill: Etiology and management | |
| Pace et al. | The effect of the vagus nerves on the bradycardia and ventricular arrhythmias induced by digitoxin and digoxin | |
| SU1664323A1 (ru) | ÐаÑЎОПпÑПÑекÑПÑМПе ÑÑеЎÑÑвП "ÐОлЎÑÐŸÐœÐ°Ñ | |
| Watkins et al. | Reduction of beta-blocking drugs in hypertensive patients treated with minoxidil. | |
| US5326774A (en) | Pharmaceutical preparation of antihypertensive, antianginal, antiarrhythmic and antiglaucomic action | |
| Gould et al. | Phentolamine use in congestive heart failure | |
| LEVY | Drugs in the treatment of heart disease | |
| KR20210131252A (ko) | ë¹íì± ì¬ê·ŒìŠ ì¹ë£ì© ìœí ì¡°ì±ë¬Œ ë° ê·ž ì¡°ì±ë¬Œì ì¬ì©íë ì¹ë£ë°©ë² | |
| WO2016089251A1 (ru) | ЀаÑЌаÑевÑОÑеÑÐºÐ°Ñ ÐºÐŸÐŒÐ¿ÐŸÐ·ÐžÑÐžÑ ÐŽÐ»Ñ ÐºÐŸÑÑекÑОО ÑОЌпÑПЌПв ОлО леÑÐµÐœÐžÑ Ð°ÑÑеМОО О/ОлО ÑОМЎÑПЌа Ñ ÑПМОÑеÑкПй ÑÑÑалПÑÑО | |
| Keys et al. | Production of Bradycardia in Normal Man by Neosynephrin (1-α-hydroxy-β-methylamino-3-hydroxy-ethylbenzene hydrochloride) |